Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163 is registered in ClinicalTrials.gov with Zenas BioPharma (USA), LLC as lead sponsor.

NCT NCT06559163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06559163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus
Lead sponsor
Zenas BioPharma (USA), LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 17, 2024
Completion date
December 31, 2026
Enrollment
190 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus